Blue Trust Inc’s Soleno Therapeutics SLNO Stock Holding History

Blue Trust Inc’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11	Closed	-$509	–	2660
2025 Q4	$509	Buy	+11	New	+$603	﹤0.01%	2392

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Blue Trust Inc's SLNO Position: Q1 2026 in Review

Blue Trust Inc sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 11 shares — an estimated $509 sold.

Blue Trust Inc first reported a position in SLNO in Q4 2025 and held it in 1 quarter. The position peaked at $509 in Q4 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Blue Trust Inc reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
Blue Trust Inc sold 11 Soleno Therapeutics shares in Q1 2026, an estimated $509.
Blue Trust Inc first reported a position in Soleno Therapeutics in Q4 2025 and held it in 1 quarter.
Blue Trust Inc's Soleno Therapeutics position peaked at $509 in Q4 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Blue Trust Inc's 13F filing for Q1 2026, filed 20 Apr 2026.